Apoptosis-related factors are relevant to progression of pancreatic neuroendocrine tumors

Background Multidisciplinary therapy centered on antitumor drugs is indicated in patients with unresectable pancreatic neuroendocrine tumors (PanNET). However, the criteria for selection of optimal therapeutic agents is controversial. The aim of this study was to assess the malignancy of PanNET for optimal therapeutic drug selection. Methods Forty-seven patients with PanNET who underwent surgery were reviewed retrospectively, and immunohistochemical characteristics, including expression of GLUT1, SSTR2a, SSTR5, Survivin, X-chromosome-linked inhibitor of apoptosis protein (XIAP), and Caspase3 in the resected specimens, were investigated. Relapse-free survival (RFS) and overall survival (OS) were evaluated with regard to the characteristics using the Kaplan–Meier method and compared with the log-rank test. Results GLUT1 expression showed significant correlation with sex ( p = 0.036) and mitotic rate ( p = 0.048). Survivin and XIAP expression showed significant correlation with T-stage ( p = 0.014 and 0.009), p-Stage ( p = 0.028 and 0.045), and mitotic rate ( p = 0.023 and 0.007). XIAP expression also significantly influenced OS ( p = 0.044). Conclusions Survivin and XIAP correlated with grade of malignancy, and expression of XIAP in particular was associated with a poor prognosis. Expression of these proteins may be a useful indicator to select optimal therapeutic agents in PanNET.